Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06174220Phase 2Recruiting

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Role: collaborator

NCT03692312Phase 2Completed

Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy

Role: lead

NCT02858908Phase 2Completed

Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

Role: lead

NCT07119775Unknown

Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy

Role: lead

NCT05004129Phase 2Recruiting

Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Role: lead

All 5 trials loaded